MAPK13 inhibitor (Nupeak Therapeutics)

N/A

Report date: 2025/01/26 15:53:53
NME

Base Information

Drug NameMAPK13 inhibitor (Nupeak Therapeutics)
Drug Alias Namemitogen-activated protein kinase 13 inhibitor (Nupeak Therapeutics)MAPK 13 inhibitor (University of Washington)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actionp38-δ mitogen-activated protein kinase degraders
Targetsp38-δ mitogen-activated protein kinase
Therapy Area/IndicationsRespiratory Tract DiseasesBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Washington
China Registration ClassN/A

Develop Information

Active CompaniesNupeak Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsRespiratory Tract DiseasesBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A